Search for a command to run...
No recent news available for this stock.
Glenmark Pharmaceuticals Ltd. demonstrates significant challenges in growth and profitability metrics compared to its peers, exhibiting a decline in revenue and negative profit margins, which places it at a disadvantage in the competitive pharmaceuticals sector. This analysis highlights both the underperformance of Glenmark and identifies peer companies that exhibit stronger financial health and growth potential.
Strong revenue growth (YoY: 13.28%) and the highest ROE (16.63%) among peers.
Excellent profitability with a PE of 15.50 and significant revenue growth.
Outstanding growth trajectory with a YoY revenue increase of 18.12% and strong financial metrics.